Searching for an effective prediction tool for prostate cancer

UCSF is West Coast leader for the innovative, minimally invasive treatment for prostate cancer patients.

In this episode, Janelle Bunce, PA-C, highlights the role that advanced practice providers can play in filling the gaps created by the growing workforce shortages in urology.

The EV-302 trial is the confirmatory trial for the FDA’s accelerated approval of pembrolizumab plus enfortumab vedotin for the first-line treatment of patients with locally advanced or metastatic urothelial carcinoma.

"We're excited that the FDA approval of this radiotracer gives us yet more tools at our disposal to diagnose prostate cancer in all its forms, from early to late in the disease process," says David M. Schuster, MD, FACR.

Proper coding for percutaneous nephrolithotomy includes code 50081.

Liposomal tacrolimus led to improvements in hematuria, bleeding sites on cystoscopy, microscopic urine analysis for red blood cells, and urinary symptoms.